Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by... | May 11, 2023

Related Keywords

United States ,Keith Kaye ,Nasdaq ,Centers For Disease ,Drug Administration ,Exchange Commission ,Innoviva Inc ,Division Of Allergy ,Entasis Therapeutics Inc ,Securities Exchange ,Glaxo Group Limited ,Antimicrobial Drugs Advisory Committee ,Jolla Pharmaceutical Company ,World Health Organization ,Innoviva Specialty Therapeutics ,Lancet Infectious Diseases ,Serious Infections ,Acinetobacter Baumannii Calcoaceticus Complex ,Infectious Diseases ,Rutgers Robert Wood Johnson Medical ,Disease Control ,New Drug Application ,Priority Review ,Drugs Advisory Committee ,Prescription Drug User Fee Act ,Qualified Infectious Disease Product ,Specialty Therapeutics ,Specialty Therapeutic ,Long Acting Beta ,Collaboration Agreement ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Financial Condition ,Annual Report ,Quarterly Reports ,Risk Factors ,Clinical Presentation ,Molecular Bacterial Pathogenesis Volume ,Health Organization ,Rev Drug ,Antibiotic Resistance ,Patient Safety ,Innoviva ,Nc Stock Exchange ,News ,Information ,Press Release ,Us ,The ,First ,Therapy ,Under ,Investigation ,Or ,Treatment ,F ,Bacterial ,Pneumonia ,End ,Aused Inva Us45781m1018 ,